Treatment of proliferative lupus nephritis: a slowly changing landscape (Q37822658)

23 August 2017

1 reference

title

Treatment of proliferative lupus nephritis: a slowly changing landscape (English)

1 reference

23 August 2017

1 reference

1

Vladimir Tesar

1 reference

23 August 2017

Zdenka Hruskova

2

1 reference

PubMed ID

21173789

23 August 2017

language of work or name

English

0 references

publication date

21 December 2010

1 reference

Nature Reviews Nephrology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

2

1 reference

23 August 2017

96-109

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.170

23 August 2017

0 references

cites work

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

European consensus statement on the terminology used in the management of lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Therapeutic options for resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Factors associated with poor outcomes in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Outcomes in African Americans and Hispanics with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Severe lupus nephritis: racial differences in presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Demographic differences in the development of lupus nephritis: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Reliability of histologic scoring for lupus nephritis: a community-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Value of a complete or partial remission in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

How did cyclophosphamide become the drug of choice for lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Treatment of lupus nephritis--the advantages of a flexible approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Can we personalize treatment for kidney diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Lupus nephritis: lessons from murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Intravenous immunoglobulin: adverse effects and safe administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biomarkers in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biomarkers for lupus nephritis: the quest continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Biomarkers of lupus nephritis determined by serial urine proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Baseline characteristics of a multiethnic lupus cohort: PROFILE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Outcome criteria for lupus nephritis trials: a critical overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The long-term outcome of 93 patients with proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Clinical and prognostic value of serial renal biopsies in lupus nephritis

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

31 March 2020

12 December 2020

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Effect of treatment on the evolution of renal abnormalities in lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Cyclophosphamide and lupus nephritis: when, how, for how long?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Maintenance treatment of proliferative lupus nephritis can be discontinued after remission in some patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Cyclosporine (CsA) in lupus nephritis: assessing the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Treatment of lupus nephritis with cyclosporine - an outcome analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Therapy: rituximab and PML risk-informed decisions needed!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.170

Induction and maintenance therapy in proliferative lupus nephritis.

31 March 2020

1 reference

12 December 2020

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

1 reference

12 December 2020

Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis

1 reference

12 December 2020

Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.

1 reference

12 December 2020

Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.

1 reference

12 December 2020

Baseline characteristics of a multiethnic lupus cohort: PROFILE

1 reference

12 December 2020

THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS

1 reference

12 December 2020

Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis

1 reference

12 December 2020

1 reference

12 December 2020

High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.170

1 reference

PubMed ID

21173789

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

21173789